Drugs / Healive
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT06058416 | Oct 2023 → Mar 2028 expected | hepatitis A virus infection | Sinovac Biotech Co., Ltd | Active not recruiting | No outcome recorded |
| Phase 4 | NCT01252680 | Apr 2010 → Feb 2011 | hepatitis A virus infection | Sinovac Biotech Co., Ltd | Completed | No outcome recorded |
| Phase 4 | NCT00534885 | Mar 2006 → Oct 2017 | hepatitis A virus infection | Sinovac Biotech Co., Ltd | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2023-06-30 | Sinovac Biotech Co., Ltd | Results 一项长达15年的随访研究显示：甲肝灭活疫苗孩尔来福®能提供至少30年的有效保护 sinovac.com ↗
研究结果显示，孩尔来福 ® 接种后各时间点的抗体水平均显著高于对照组，差异有统计学意义。 |
| 2020-03-30 | Sinovac Biotech Co., Ltd | Results 儿童接种孩尔来福 ® 后11年随访研究显示：甲肝灭活疫苗能至少提供30年的有效保护 sinovac.com ↗
与贺福立适®组相比，孩尔来福®组在儿童接种11年之后免疫原性更优。 |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2023-06-30 | Sinovac Biotech Co., Ltd | 一项长达15年的随访研究显示：甲肝灭活疫苗孩尔来福®能提供至少30年的有效保护 sinovac.com ↗ |
| 2020-03-30 | Sinovac Biotech Co., Ltd | 儿童接种孩尔来福 ® 后11年随访研究显示：甲肝灭活疫苗能至少提供30年的有效保护 sinovac.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Healive | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01252680 ↗ |
| Modality | Vaccine | “preservative-free inactivated hepatitis A vaccine” NCT00534885 ↗ |